These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31183847)

  • 21. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
    Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
    Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation.
    Colàs-Campàs L; Royo JL; Montserrat MV; Marzo C; Molina-Seguín J; Benabdelhak I; Cambray S; Purroy F
    Pharmacogenomics J; 2018 Sep; 18(5):652-656. PubMed ID: 29273767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.
    Cotté FE; Benhaddi H; Duprat-Lomon I; Doble A; Marchant N; Letierce A; Huguet M
    Clin Ther; 2014 Sep; 36(9):1160-8. PubMed ID: 25151574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists.
    Visser C; Biedermann JS; Nierman MC; van der Meer FJM; Gulpen AJW; Moors YCF; Cannegieter SC; Lijfering WM; Kruip MJHA;
    Thromb Haemost; 2022 Mar; 122(3):377-385. PubMed ID: 35245945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Van Der Meersch H; De Bacquer D; De Vriese AS
    Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.
    Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB
    J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Singer DE; Albers GW; Dalen JE; Fang MC; Go AS; Halperin JL; Lip GYH; Manning WJ
    Chest; 2008 Jun; 133(6 Suppl):546S-592S. PubMed ID: 18574273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor anticoagulation relates to extended access times for cardioversion and is associated with long-term major cardiac and cerebrovascular events.
    Erküner Ö; Claessen R; Pisters R; Schulmer G; Ramaekers R; Sonneveld L; Dudink E; Lankveld T; Limantoro I; Weijs B; Pison L; Blaauw Y; de Vos CB; Crijns HJ
    Int J Cardiol; 2016 Dec; 225():337-341. PubMed ID: 27756038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Br J Haematol; 2010 May; 149(4):598-605. PubMed ID: 20151978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association.
    Hernández Madrid A; Potpara TS; Dagres N; Chen J; Larsen TB; Estner H; Todd D; Bongiorni MG; Sciaraffia E; Proclemer A; Cheggour S; Amara W; Blomstrom-Lundqvist C
    Europace; 2016 Mar; 18(3):463-7. PubMed ID: 26899998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
    Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. POST-NOAC: Portuguese observational study of intracranial hemorrhage on non-vitamin K antagonist oral anticoagulants.
    Marques-Matos C; Alves JN; Marto JP; Ribeiro JA; Monteiro A; Araújo J; Silva F; Grenho F; Viana-Baptista M; Sargento-Freitas J; Pinho J; Azevedo E
    Int J Stroke; 2017 Aug; 12(6):623-627. PubMed ID: 27903938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study.
    Barrios V; Escobar C; Prieto L; Osorio G; Polo J; Lobos JM; Vargas D; García N
    Rev Esp Cardiol (Engl Ed); 2015 Sep; 68(9):769-76. PubMed ID: 26169326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.
    Pastori D; Farcomeni A; Saliola M; Del Sole F; Pignatelli P; Violi F; Lip GYH;
    Eur J Intern Med; 2018 Aug; 54():34-39. PubMed ID: 29655807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.